Skip to main content
. 2022 May 25;6(6):434–440. doi: 10.1002/jgh3.12773

Table 4.

Diagnostic performance of the American Society of Gastrointestinal Endoscopy (ASGE) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines for common bile duct (CBD) stone prediction

CBD stone status, n (%) Diagnostic properties (95% CI)
Guidelines classification Positive Negative Sensitivity Specificity PPV LHR+ AUC
ASGE 2019
Low risk 1 (0.3) 11 (5.4) 0.3 (0.0–1.7) 94.6 (90.5–97.3) 8.3 (0.2–38.5) 0.06 (0.01–0.44) 0.69 (0.65–0.73)
Intermediate risk 50 (15.7) 96 (47.3) 15.7 (11.9–20.2) 52.7 (45.6–59.7) 34.2 (26.6–42.5) 0.33 (0.25–0.44)
High risk 267 (84.0) 96 (47.3) 84.0 (79.5–87.8) 52.7 (45.6–59.7) 73.6 (68.7–78.1) 1.78 (1.52–2.07)
ESGE
Low risk 8 (2.5) 22 (10.8) 2.5 (1.1–4.9) 89.2 (84.1–93.1) 26.7 (12.3–45.9) 0.23 (0.11–0.51) 0.68 (0.64–0.72)
Intermediate risk 58 (18.2) 91 (44.8) 18.2 (14.2–22.9) 55.2 (48.1–62.1) 38.9 (31.1–47.2) 0.41 (0.31–0.54)
High risk 252 (79.2) 90 (44.3) 79.2 (74.4–83.6) 55.7 (48.5–62.6) 73.7 (68.7–78.3) 1.79 (1.52–2.11)

AUC, area under the receiver operating characteristic curve; CI, confidence interval; LHR+, positive likelihood ratio; PPV, positive predictive value.